ERBB2 and neoplasm: This platform was previously shown to be successful in detecting rare “HER2-activated” circulating tumor cells in HER2-negative metastatic breast cancer patients [10], indicating its high sensitivity and ability to provide potentially actionable information beyond the genomic and transcriptomic levels.